Eli Lilly Stock Crumbles As Covid Antibodies Hammer Sales, 2021 Outlook

Eli Lilly stock crumbled Tuesday after the pharmaceutical giant lagged Wall Street’s first-quarter expectations and cut its 2021 outlook on light Covid-19 treatment sales.
Read More